Tianjin Ringpu Bio-TechnologyLtd Future Growth
Future criteria checks 3/6
Tianjin Ringpu Bio-TechnologyLtd is forecast to grow earnings and revenue by 20.8% and 16.9% per annum respectively. EPS is expected to grow by 20.5% per annum. Return on equity is forecast to be 12.2% in 3 years.
Key information
20.8%
Earnings growth rate
20.5%
EPS growth rate
| Pharmaceuticals earnings growth | 18.5% |
| Revenue growth rate | 16.9% |
| Future return on equity | 12.2% |
| Analyst coverage | Good |
| Last updated | 27 Aug 2024 |
Recent future growth updates
Recent updates
The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More
Oct 08
Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 26Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet
Aug 23Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly
Jun 26Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)
Apr 05Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity
Mar 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,668 | 732 | 781 | 695 | 6 |
| 12/31/2025 | 3,224 | 627 | 118 | 664 | 7 |
| 12/31/2024 | 2,774 | 504 | 107 | 413 | 7 |
| 6/30/2024 | 2,354 | 434 | 186 | 437 | N/A |
| 3/31/2024 | 2,339 | 460 | 196 | 438 | N/A |
| 12/31/2023 | 2,249 | 453 | 134 | 378 | N/A |
| 9/30/2023 | 2,195 | 387 | 129 | 386 | N/A |
| 6/30/2023 | 2,170 | 385 | 156 | 462 | N/A |
| 3/31/2023 | 2,136 | 355 | 139 | 473 | N/A |
| 1/1/2023 | 2,084 | 347 | 17 | 389 | N/A |
| 9/30/2022 | 1,985 | 354 | -1 | 367 | N/A |
| 6/30/2022 | 1,875 | 349 | 0 | 317 | N/A |
| 3/31/2022 | 1,838 | 369 | -41 | 287 | N/A |
| 1/1/2022 | 2,007 | 413 | 77 | 383 | N/A |
| 9/30/2021 | 2,038 | 438 | 72 | 358 | N/A |
| 6/30/2021 | 2,117 | 454 | 87 | 408 | N/A |
| 3/31/2021 | 2,106 | 441 | 134 | 438 | N/A |
| 12/31/2020 | 2,000 | 398 | 129 | 388 | N/A |
| 9/30/2020 | 1,895 | 302 | 175 | 460 | N/A |
| 6/30/2020 | 1,737 | 255 | 183 | 417 | N/A |
| 3/31/2020 | 1,613 | 224 | 190 | 396 | N/A |
| 12/31/2019 | 1,467 | 194 | 154 | 384 | N/A |
| 9/30/2019 | 1,346 | 158 | 83 | 264 | N/A |
| 6/30/2019 | 1,260 | 137 | 56 | 216 | N/A |
| 3/31/2019 | 1,203 | 124 | 32 | 167 | N/A |
| 12/31/2018 | 1,190 | 119 | 62 | 175 | N/A |
| 9/30/2018 | 1,179 | 108 | 40 | 155 | N/A |
| 6/30/2018 | 1,157 | 117 | 45 | 159 | N/A |
| 3/31/2018 | 1,112 | 112 | N/A | 113 | N/A |
| 12/31/2017 | 1,047 | 105 | N/A | 110 | N/A |
| 9/30/2017 | 1,008 | 136 | N/A | 152 | N/A |
| 6/30/2017 | 993 | 138 | N/A | 155 | N/A |
| 3/31/2017 | 988 | 140 | N/A | 185 | N/A |
| 12/31/2016 | 970 | 133 | N/A | 208 | N/A |
| 9/30/2016 | 943 | 129 | N/A | 214 | N/A |
| 6/30/2016 | 905 | 113 | N/A | 221 | N/A |
| 3/31/2016 | 832 | 108 | N/A | 223 | N/A |
| 12/31/2015 | 793 | 110 | N/A | 225 | N/A |
| 9/30/2015 | 690 | 68 | N/A | 172 | N/A |
| 6/30/2015 | 639 | 43 | N/A | 131 | N/A |
| 3/31/2015 | 625 | 34 | N/A | 140 | N/A |
| 12/31/2014 | 585 | 27 | N/A | 130 | N/A |
| 9/30/2014 | 669 | 95 | N/A | 138 | N/A |
| 6/30/2014 | 676 | 113 | N/A | 136 | N/A |
| 3/31/2014 | 722 | 140 | N/A | 116 | N/A |
| 12/31/2013 | 755 | 152 | N/A | 89 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300119's forecast earnings growth (20.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 300119's earnings (20.8% per year) are forecast to grow slower than the CN market (23.7% per year).
High Growth Earnings: 300119's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300119's revenue (16.9% per year) is forecast to grow faster than the CN market (13.4% per year).
High Growth Revenue: 300119's revenue (16.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300119's Return on Equity is forecast to be low in 3 years time (12.2%).